[go: up one dir, main page]

PH12020500255A1 - Use of nk-1 receptor antagonist serlopitant in pruritus - Google Patents

Use of nk-1 receptor antagonist serlopitant in pruritus

Info

Publication number
PH12020500255A1
PH12020500255A1 PH12020500255A PH12020500255A PH12020500255A1 PH 12020500255 A1 PH12020500255 A1 PH 12020500255A1 PH 12020500255 A PH12020500255 A PH 12020500255A PH 12020500255 A PH12020500255 A PH 12020500255A PH 12020500255 A1 PH12020500255 A1 PH 12020500255A1
Authority
PH
Philippines
Prior art keywords
serlopitant
pruritus
receptor antagonist
receptor antagonists
additional
Prior art date
Application number
PH12020500255A
Inventor
Xiaoming Zhang
Edward F Schnipper
Andrew J Perlman
James W Larrick
Original Assignee
Menlo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/925,509 external-priority patent/US8906951B1/en
Application filed by Menlo Therapeutics Inc filed Critical Menlo Therapeutics Inc
Publication of PH12020500255A1 publication Critical patent/PH12020500255A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
PH12020500255A 2013-06-24 2020-02-04 Use of nk-1 receptor antagonist serlopitant in pruritus PH12020500255A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361838784P 2013-06-24 2013-06-24
US13/925,509 US8906951B1 (en) 2013-06-24 2013-06-24 Use of NK-1 receptor antagonists in pruritus
PCT/US2014/043811 WO2014209962A1 (en) 2013-06-24 2014-06-24 Use of nk-1 receptor antagonist serlopitant in pruritus

Publications (1)

Publication Number Publication Date
PH12020500255A1 true PH12020500255A1 (en) 2021-02-22

Family

ID=51230173

Family Applications (2)

Application Number Title Priority Date Filing Date
PH12015502777A PH12015502777A1 (en) 2013-06-24 2015-12-14 Use of nk-1 receptor antagonist serlopitant in pruritus
PH12020500255A PH12020500255A1 (en) 2013-06-24 2020-02-04 Use of nk-1 receptor antagonist serlopitant in pruritus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PH12015502777A PH12015502777A1 (en) 2013-06-24 2015-12-14 Use of nk-1 receptor antagonist serlopitant in pruritus

Country Status (13)

Country Link
EP (1) EP3013336A1 (en)
JP (2) JP2016523260A (en)
KR (1) KR20160023692A (en)
CN (1) CN105473138A (en)
AU (2) AU2014302694B2 (en)
BR (1) BR112015031724A2 (en)
CA (1) CA2915474A1 (en)
HK (1) HK1223820A1 (en)
IL (1) IL243189A0 (en)
MX (2) MX366728B (en)
PH (2) PH12015502777A1 (en)
RU (1) RU2666219C2 (en)
WO (1) WO2014209962A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
JP6741655B2 (en) 2014-09-19 2020-08-19 ヘロン セラピューティクス， インコーポレイテッドＨｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Emulsion formulation of aprepitant
AU2016226006B2 (en) * 2015-03-04 2021-03-04 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US9974742B2 (en) 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
WO2017135923A1 (en) * 2016-02-01 2017-08-10 Heron Therapeutics, Inc. Emulsion comprising an nk-1 receptor antagonist
BR112018077300A2 (en) * 2016-06-29 2019-04-02 Menlo Therapeutics Inc. use of neurokinin-1 antagonists to treat various pruritic conditions
US11549147B2 (en) * 2017-09-13 2023-01-10 Vanda Pharmaceuticals Inc. Treatment of atopic dermatitis with tradipitant
CN111886025A (en) * 2017-11-01 2020-11-03 新加坡国立大学 Use of serotonergic agents for the treatment of virus-induced thrombocytopenia
AU2019213835B2 (en) * 2018-01-31 2024-12-19 Twi Biotechnology, Inc. Topical formulations comprising tofacitinib
CN115015440B (en) * 2022-07-08 2024-10-15 江苏杜瑞制药有限公司 Method for detecting nalfurorphine in biological sample
CN117503699A (en) * 2023-12-08 2024-02-06 斯坦德医药研发(江苏)有限公司 Aprepitant oral liquid preparation and preparation method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100565A1 (en) 2001-09-21 2003-05-29 Boehringer Ingelheim International Gmbh Method for the treatment or prevention of atopic dermatitis
CN100582093C (en) * 2004-01-27 2010-01-20 默克公司 Hydroisoindoline tachykinin receptor antagonists
AR047439A1 (en) * 2004-01-27 2006-01-18 Merck & Co Inc TAQUIQUININE HYDROISOINDOLINE RECEIVER ANTAGONISTS
CA2612844A1 (en) 2005-07-11 2007-01-18 Merck & Co., Inc. Process for making hydroisoindoline tachykinin receptor antagonists
EP1937264B1 (en) 2005-10-04 2011-06-08 Merck Sharp & Dohme Corp. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
WO2007146224A2 (en) 2006-06-12 2007-12-21 Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
WO2008030389A2 (en) * 2006-09-06 2008-03-13 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
WO2008054690A2 (en) 2006-11-02 2008-05-08 Merck & Co., Inc. Polymorphs of a hydroisoindoline tachykinin receptor antagonist
AU2008233232A1 (en) 2007-03-29 2008-10-09 Merck Sharp & Dohme Corp. Combination therapy for the treatment-of lower urinary tract symptoms
RU2370265C1 (en) * 2008-03-04 2009-10-20 Лев Давидович Раснецов Gel, possessing anti- inflammatory and antiallergic effect

Also Published As

Publication number Publication date
MX2015017763A (en) 2016-06-21
CN105473138A (en) 2016-04-06
PH12015502777A1 (en) 2016-03-21
JP2019142960A (en) 2019-08-29
IL243189A0 (en) 2016-02-29
MX2019008643A (en) 2019-09-10
RU2666219C2 (en) 2018-09-06
KR20160023692A (en) 2016-03-03
EP3013336A1 (en) 2016-05-04
HK1223820A1 (en) 2017-08-11
JP2016523260A (en) 2016-08-08
BR112015031724A2 (en) 2017-07-25
AU2014302694A1 (en) 2016-01-07
AU2014302694B2 (en) 2019-10-17
AU2020200259A1 (en) 2020-02-06
RU2015154037A (en) 2017-07-28
WO2014209962A1 (en) 2014-12-31
CA2915474A1 (en) 2014-12-31
MX366728B (en) 2019-07-22

Similar Documents

Publication Publication Date Title
PH12020500255A1 (en) Use of nk-1 receptor antagonist serlopitant in pruritus
PH12016500642B1 (en) Selective substituted quinoline compounds
MX2021008113A (en) Methods for treating or preventing asthma by administering an il-4r antagonist.
MX368455B (en) Tetrahydropyrazolopyrimidine compounds.
JOP20140141B1 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
MX2015002292A (en) Methods for treating or preventing asthma by administering an il-4r antagonist.
MX365242B (en) Use of cxcr4 antagonists.
MX2020001756A (en) Benzoquinolone inhibitors of vmat2.
SA516370641B1 (en) Heterocyclic compounds and methods of use
MX2016004741A (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent.
ZA201506131B (en) Kv1.3 antagonists and methods of use
MX2016006975A (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases.
MX2016007947A (en) Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features.
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
PH12017501214A1 (en) Cgrp antagonist peptides
MX375355B (en) Compositions and methods for treating intracerebral hemorrhage
EP2952204A4 (en) Pharmaceutical composition for reducing or inhibiting scar formation, containing bmp-7 and diluting agent
ME03086B (en) Kv1.3 antagonists and methods of use
MX2019009243A (en) Methods for treating or preventing asthma by administering an il-4r antagonist.
UA88242U (en) Use of raleukin (antagonist of interleukin-1 receptor) as hypoglycemic agent